Sun Pharma Advanced Research Company Ltd.
NSE: SPARC | BSE: 532872
₹199.58
₹2.60
(1.32%)
As on 02-Sep-2026IST
Market cap
₹6,486 Cr
Revenue (TTM)
₹1,909 Cr
P/E Ratio
4.1
P/B Ratio
4.9
Div. Yield
0 %
Quality Score
3/10
Growth Score
7/10
Valuation Score
6/10
Momentum Score
9/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹1,584 Cr
-
ROE
276.9 %
-
ROCE
163.9 %
-
Industry P/E
42.09
-
EV/EBITDA
4.3
-
Debt to Equity
0.4
-
Book Value
₹40.6
-
EPS
₹49.2
-
Face value
1
-
Shares outstanding
324,521,588
10 Years Aggregate
CFO
₹-2,151.04 Cr
EBITDA
₹-488.86 Cr
Net Profit
₹-527.51 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
| 48.4 | -3.2 | 1.6 | 40.7 | -7.3 | -8.0 | -6.1 |
|
BSE Healthcare
| 18.0 | 0.9 | 10.3 | 17.1 | 22.7 | 14.0 | 12.3 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
| -33.0 | -34.8 | 37.5 | -27.3 | 45.9 | 23.7 | -17.5 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharma Adv Resrc
|
199.6 | 6,485.6 | 1,909.5 | 1,584.3 | 84.2 | -- | 4.1 | 4.9 |
| 3,134.9 | 25,690.3 | 1,461.8 | 387.4 | 34.5 | 25.2 | 66.5 | 14.9 | |
| 826.9 | 16,239.1 | 7,784.0 | 688.5 | 10.6 | 14 | 23.4 | 2.8 | |
| 458.3 | 17,559.3 | 2,141.5 | 58.5 | 5.8 | 3.3 | 165.3 | 4.6 | |
| 831.8 | 20,598.1 | 5,632.3 | 662.4 | 17.2 | 14.3 | 31.1 | 4.2 | |
| 1,544.4 | 17,715.2 | 1,543.3 | -48.6 | 3.6 | -0.6 | -- | 3.0 | |
| 213.8 | 28,444.3 | 9,205.3 | -371.8 | 1.7 | -3.8 | -- | 3.6 | |
| 1,828.8 | 30,238.5 | 1,935.8 | 288.2 | 20.6 | 29.8 | 104.9 | 22.5 | |
| 398.6 | 16,086.2 | 3,600.2 | 221.0 | 9.7 | 5.6 | 72.8 | 3.4 | |
| 1,904.3 | 30,950.7 | 3,564.0 | 414.0 | 15.3 | 8.4 | 75.7 | 6.1 |
Shareholding Pattern
View DetailsNews & Analysis
All News
3 min read•By Research Desk
About Sun Pharma Adv Resrc
Sun Pharma Advanced Research Company Limited, a clinical-stage biopharmaceutical company, engages in the research and development of pharmaceutical products in India and internationally. It develops products with a therapeutic focus on oncology and... immunology. The company is also developing Vodobatinib (SCO-088), a BCR-ABL inhibitor, for the treatment of refractory chronic myelogenous leukemia that is in phase 2 clinical trial; and Vibozilimod (SCD-044), a selective sphingosine-1-phosphate receptor 1 (S1PR1) agonist, for the treatment of psoriasis and atopic dermatitis that is in phase 2 clinical trial. In addition, it develops SCD-153 for the treatment of alopecia areata; and SBO-154, an anti-MUC-1 ADC, for the treatment of multiple tumors that is in preclinical trials. The company was incorporated in 2006 and is based in Mumbai, India. Read more
-
Incorporated
2006
-
Chairman
Dilip S Shanghvi
-
Managing Director
--
-
Group
Sun Pharma
-
Headquarters
Vadodara, Gujarat
-
Website
Looking for more details about Sun Pharma Advanced Research Company Ltd.’s IPO? Explore our IPO Details page.
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Sun Pharma Adv Resrc
What is the current share price of Sun Pharma Advanced Research Company Ltd Today?
The share price of Sun Pharma Advanced Research Company Ltd is ₹199.58 (NSE) and ₹199.85 (BSE) as of 02-Sep-2026 IST. Sun Pharma Advanced Research Company Ltd has given a return of -7.28% in the last 3 years.
What is the current PB & PE ratio of Sun Pharma Advanced Research Company Ltd?
The P/E ratio of Sun Pharma Advanced Research Company Ltd is 4.09 times as on 02-Sep-2026, a 90 discount to its peers’ median range of 42.09 times.
The P/B ratio of Sun Pharma Advanced Research Company Ltd is 4.92 times as on 02-Sep-2026, a 15 premium to its peers’ median range of 4.27 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2026 |
2.39 |
2.78 |
2025 |
0.00 |
-22.14 |
2024 |
0.00 |
95.47 |
2023 |
0.00 |
11.36 |
2022 |
0.00 |
-39.75 |
What is the 52 Week High and Low of Sun Pharma Advanced Research Company Ltd?
The 52-week high and low of Sun Pharma Advanced Research Company Ltd are Rs 289.00 and Rs 108.00 as of 02-Sep-2026.
What is the market cap of Sun Pharma Advanced Research Company Ltd?
Sun Pharma Advanced Research Company Ltd has a market capitalisation of ₹ 6,486 Cr as on 02-Sep-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Sun Pharma Advanced Research Company Ltd?
Before investing in Sun Pharma Advanced Research Company Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.